vs
ARDELYX, INC.（ARDX）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是ARDELYX, INC.的2.1倍（$200.5M vs $94.5M），ROGERS CORP净利率更高（2.2% vs -39.8%，领先42.0%），ARDELYX, INC.同比增速更快（27.5% vs 5.2%），过去两年ARDELYX, INC.的营收复合增速更高（13.6% vs -3.3%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ARDX vs ROG — 直观对比
营收规模更大
ROG
是对方的2.1倍
$94.5M
营收增速更快
ARDX
高出22.2%
5.2%
净利率更高
ROG
高出42.0%
-39.8%
两年增速更快
ARDX
近两年复合增速
-3.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $200.5M |
| 净利润 | $-37.6M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | — | — |
| 净利率 | -39.8% | 2.2% |
| 营收同比 | 27.5% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $-0.15 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXROG
| Q1 26 | $94.5M | $200.5M | ||
| Q4 25 | $125.2M | $201.5M | ||
| Q3 25 | $110.3M | $216.0M | ||
| Q2 25 | $97.7M | $202.8M | ||
| Q1 25 | $74.1M | $190.5M | ||
| Q4 24 | $116.1M | $192.2M | ||
| Q3 24 | $98.2M | $210.3M | ||
| Q2 24 | $73.2M | $214.2M |
净利润ARDXROG
| Q1 26 | $-37.6M | $4.5M | ||
| Q4 25 | $-407.0K | $4.6M | ||
| Q3 25 | $-969.0K | $8.6M | ||
| Q2 25 | $-19.1M | $-73.6M | ||
| Q1 25 | $-41.1M | $-1.4M | ||
| Q4 24 | $4.6M | $-500.0K | ||
| Q3 24 | $-809.0K | $10.7M | ||
| Q2 24 | $-16.5M | $8.1M |
毛利率ARDXROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 91.3% | 31.5% | ||
| Q3 25 | 96.4% | 33.5% | ||
| Q2 25 | 87.3% | 31.6% | ||
| Q1 25 | 83.4% | 29.9% | ||
| Q4 24 | 84.3% | 32.1% | ||
| Q3 24 | 84.0% | 35.2% | ||
| Q2 24 | 87.1% | 34.1% |
营业利润率ARDXROG
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 3.5% | ||
| Q3 25 | 4.2% | 7.3% | ||
| Q2 25 | -14.7% | -33.3% | ||
| Q1 25 | -49.0% | -0.2% | ||
| Q4 24 | 7.0% | -6.6% | ||
| Q3 24 | 2.3% | 6.9% | ||
| Q2 24 | -18.6% | 5.3% |
净利率ARDXROG
| Q1 26 | -39.8% | 2.2% | ||
| Q4 25 | -0.3% | 2.3% | ||
| Q3 25 | -0.9% | 4.0% | ||
| Q2 25 | -19.5% | -36.3% | ||
| Q1 25 | -55.5% | -0.7% | ||
| Q4 24 | 4.0% | -0.3% | ||
| Q3 24 | -0.8% | 5.1% | ||
| Q2 24 | -22.5% | 3.8% |
每股收益（稀释后）ARDXROG
| Q1 26 | $-0.15 | $0.25 | ||
| Q4 25 | $-0.01 | $0.20 | ||
| Q3 25 | $0.00 | $0.48 | ||
| Q2 25 | $-0.08 | $-4.00 | ||
| Q1 25 | $-0.17 | $-0.08 | ||
| Q4 24 | $0.01 | $-0.04 | ||
| Q3 24 | $0.00 | $0.58 | ||
| Q2 24 | $-0.07 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $195.8M |
| 总债务越低越好 | $203.5M | — |
| 股东权益账面价值 | $148.6M | $1.2B |
| 总资产 | $504.5M | $1.4B |
| 负债/权益比越低杠杆越低 | 1.37× | — |
8季度趋势，按日历期对齐
现金及短期投资ARDXROG
| Q1 26 | $238.1M | $195.8M | ||
| Q4 25 | $68.0M | $197.0M | ||
| Q3 25 | $42.7M | $167.8M | ||
| Q2 25 | $90.0M | $157.2M | ||
| Q1 25 | $30.8M | $175.6M | ||
| Q4 24 | $64.9M | $159.8M | ||
| Q3 24 | $47.4M | $146.4M | ||
| Q2 24 | $41.9M | $119.9M |
总债务ARDXROG
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
股东权益ARDXROG
| Q1 26 | $148.6M | $1.2B | ||
| Q4 25 | $166.9M | $1.2B | ||
| Q3 25 | $154.3M | $1.2B | ||
| Q2 25 | $139.5M | $1.2B | ||
| Q1 25 | $145.7M | $1.3B | ||
| Q4 24 | $173.3M | $1.3B | ||
| Q3 24 | $158.3M | $1.3B | ||
| Q2 24 | $147.0M | $1.3B |
总资产ARDXROG
| Q1 26 | $504.5M | $1.4B | ||
| Q4 25 | $501.6M | $1.4B | ||
| Q3 25 | $486.2M | $1.4B | ||
| Q2 25 | $466.8M | $1.5B | ||
| Q1 25 | $410.2M | $1.5B | ||
| Q4 24 | $435.8M | $1.5B | ||
| Q3 24 | $367.9M | $1.5B | ||
| Q2 24 | $343.5M | $1.5B |
负债/权益比ARDXROG
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流ARDXROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $21.0M | $46.9M | ||
| Q3 25 | $365.0K | $28.9M | ||
| Q2 25 | $-25.3M | $13.7M | ||
| Q1 25 | $-38.5M | $11.7M | ||
| Q4 24 | $9.8M | $33.7M | ||
| Q3 24 | $501.0K | $42.4M | ||
| Q2 24 | $-19.4M | $22.9M |
自由现金流ARDXROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $20.6M | $42.2M | ||
| Q3 25 | $209.0K | $21.2M | ||
| Q2 25 | $-26.0M | $5.6M | ||
| Q1 25 | $-38.8M | $2.1M | ||
| Q4 24 | $9.2M | $18.3M | ||
| Q3 24 | $364.0K | $25.2M | ||
| Q2 24 | $-19.5M | $8.8M |
自由现金流率ARDXROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 16.4% | 20.9% | ||
| Q3 25 | 0.2% | 9.8% | ||
| Q2 25 | -26.6% | 2.8% | ||
| Q1 25 | -52.3% | 1.1% | ||
| Q4 24 | 7.9% | 9.5% | ||
| Q3 24 | 0.4% | 12.0% | ||
| Q2 24 | -26.7% | 4.1% |
资本支出强度ARDXROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.3% | 2.3% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | 0.7% | 4.0% | ||
| Q1 25 | 0.4% | 5.0% | ||
| Q4 24 | 0.5% | 8.0% | ||
| Q3 24 | 0.1% | 8.2% | ||
| Q2 24 | 0.2% | 6.6% |
现金转化率ARDXROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
ROG
暂无分部数据
